Saturday 17 October 2026
Export TLIS’s income statement to Excel — free account
Talis Biomedical Corporation
TLIS Healthcare Medical Devices
Talis Biomedical Corporation’s revenue for fiscal 2023 (year ended December 2023) was $2.1 million, down 55.7% from fiscal 2022. Operating cash flow growth for three consecutive years.
2.84
0.00
0.00%
Follow TLIS
Talis Biomedical Corporation (TLIS) P/E ratio
Talis Biomedical Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (April 2026) to 0.0× (April 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2024 | 0.0× | — |
| Dec 2023 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| Jun 2023 | 0.0× | — |
| 14 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TELA TELA Bio, Inc. compare | n/m |
| MDAI Spectral AI, Inc. compare | n/m |
| TLIS Talis Biomedical Corporation | n/m |
| RPID Rapid Micro Biosystems, Inc. compare | n/m |
| SRTS Sensus Healthcare, Inc. compare | n/m |
| MYO Myomo, Inc. compare | n/m |
| XTNT Xtant Medical Holdings, Inc. compare | n/m |
| COCH Envoy Medical, Inc. compare | n/m |
| SNWV Sanuwave Health Inc. compare | 3.0× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)